Can Lacosamide Cause Arrhythmia?
Lacosamide, an antiepileptic drug sold as Vimpat, carries a risk of cardiac arrhythmias, primarily PR interval prolongation, atrioventricular block, and atrial fibrillation or flutter. These effects stem from its sodium channel blockade, which slows cardiac conduction, especially at doses above 400 mg/day or in patients with heart disease.[1][2]
How to Prevent Arrhythmia from Lacosamide
Prevention focuses on risk assessment and monitoring:
- Screen patients for baseline cardiac issues like conduction abnormalities or heart failure via ECG before starting.
- Start at low doses (50-100 mg/day) and titrate slowly over 1-2 weeks to 200-400 mg/day.
- Avoid in patients with severe conduction disorders unless pacemaker-fitted.
- Use caution with drugs that prolong PR interval (e.g., beta-blockers, calcium channel blockers).
- Regular ECG monitoring, particularly in the elderly or those with cardiovascular risk factors, reduces incidence.[1][3]
Treating Lacosamide-Induced Arrhythmia
If arrhythmia occurs:
- Stop or reduce lacosamide immediately; symptoms often resolve within days of discontinuation.
- Manage symptomatically: IV fluids and electrolytes for mild cases; antiarrhythmics like beta-blockers for atrial fibrillation.
- For severe atrioventricular block, temporary pacing may be needed.
- Switch to alternative antiepileptics like levetiracetam if seizures persist.[1][2][4]
Who Is at Highest Risk?
Patients over 65, those with ischemic heart disease, bundle branch block, or second/third-degree AV block face elevated risks. Concomitant use of QT-prolonging drugs or sodium channel blockers (e.g., carbamazepine) amplifies effects. Label warnings highlight 0.2-0.5% incidence of serious events in trials.[2][3]
What Do Clinical Studies Show?
Pooled data from SP767/SP754/SP755 trials (n=1,931) reported PR prolongation in 7-9% at higher doses, with 0.4% discontinuations due to cardiac events. Post-marketing surveillance notes rare ventricular arrhythmias. No deaths directly linked in FDA reviews, but monitoring is standard.[1][4]
Alternatives If Arrhythmia Risk Is a Concern
Levetiracetam or lamotrigine have lower cardiac risk profiles for focal seizures. Valproate or topiramate suit broader epilepsy types without sodium channel effects. Consult neurologist for personalized switches.[3]
Sources
[1]: FDA Vimpat Label
[2]: Drugs.com Lacosamide Side Effects
[3]: Epilepsy Foundation on Lacosamide
[4]: PubMed: Cardiac Safety of Lacosamide